Paul A. Moore, PhD


Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.

Oscar Escobar-Vidarte, MD


Signaling Pathways in the Relapse of Glioblastoma

Javier Orozco-Mera, MD, FACS, MSc, and colleagues assess the signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

Alexandra Garcilazo-Reyes, MD


Oligoprogression After Immunotherapy and Targeted Therapy in Metastatic Melanoma

This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.

Laurie H. Sehn, MD


Laurie H. Sehn, MD, on the Key Takeaways From the GO29365 Study in DLBCL

The preliminary findings of the extension arm of the phase 1b/2 GO29365 study confirmed the benefits and tolerability of polatuzumab vedotin plus bendamustine and rituximab for patients with diffuse large B-cell lymphoma.

Surbhi Sidana, MD


Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment

The panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.

Brian Van Tine, MD, PhD


Neoantigen Vaccines May be Next Step in Treating Sarcomas

Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.

Ricardo Ghelman, MD, PhD


Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations

This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.

Carlos Ortiz-Hidalgo, MD


Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor

In this edition of Clinical Quandaries, Regina Barragan-Carrillo, MD, and colleagues present a case of an 18-year-old man who has a 1-month history of nonpainful right testicular enlargement.

Artak Gevorgyan, MD


How to Treat Metastatic Malignant Triton Tumor in an Adolescent

A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.

Leyla O. Shune, MD


Treatment Considerations for Bispecific Antibodies and Unmet Needs in MM

The expert panel overviews factors to consider with bispecific antibodies and offers closing insights on unmet needs in the multiple myeloma treatment space.

Mourad Tighiouart, PhD


Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.

Fredrik Schjesvold, MD, PhD


Fredrik Schjesvold, MD, PhD, Discusses the Potential of Minimal Residual Disease –Directed Treatment for Multiple Myeloma

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma.

Simon Chowdhury, MD


Metastatic CSPC: Future Directions in Care

Before closing out their discussion on novel treatment approaches to metastatic CSPC, expert panelists share hope for further evolution in care.

K.M. Monirul Islam, MD, PhD


Factors Associated With Treatment Refusal and Impact of Treatment Refusal on Survival of Patients With Small Cell Lung Cancer

Original research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.

Helena A. Yu, MD


NSCLC: Moving Second-Line Therapies to Frontline Setting

Helena A. Yu, MD, and Joshua K. Sabari, MD, look to the future of frontline treatment in EGFR exon 20–mutated non–small cell lung cancer.

Berta Hernández Marin, MD


Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected Data

Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.

Peter H. O’Donnell, MD, PhD


Emerging Data and Future Directions in UC

Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.

Jessica Freydman, PharmD


Expert Commentary on the Product Profile of Tepotinib

In an interview with ONCOLOGY®, David Hughes PharmD, BCOP, and Jessica Freydman, PharmD, offers a comprehensive review of real-world treatment considerations of tepotinib as therapy for patients with metastatic non–small cell lung cancer that have MET exon14 skipping mutations.

Xiaoli Mi, MD


Cross Q&A: The Memorial Sloan-Kettering Mavericks

The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.

Juejing Chen, MD


Ocular Toxicities of MEK Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis

Jing Han, MD, and colleagues examine the prevalence and characteristics of ocular toxicities associated with MEK inhibition.